Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
公司代碼BBNX
公司名稱Beta Bionics Inc
上市日期Jan 30, 2025
CEOSaint (Sean)
員工數量291
證券類型Ordinary Share
年結日Jan 30
公司地址11 Hughes
城市IRVINE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編92618
電話19494277785
網址https://www.betabionics.com
公司代碼BBNX
上市日期Jan 30, 2025
CEOSaint (Sean)